Norditropin Daily denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Flags Norditropin Daily as Step-Therapy

UnitedHealthcare's Commercial Medical Benefit Drug Policy treats somatropin products as therapeutically interchangeable within the somatropin class, which is the predicate for any step-therapy denial on Norditropin. Under OptumRx's preferred-product management, UHC routinely steers new starts to whichever pen device holds the current rebate position — typically Genotropin or Omnitrope — and issues a step-therapy denial when Norditropin is prescribed first-line without documented failure, intolerance, or contraindication to the preferred agent. The denial letter will cite the HGH policy by name and the formulary tier placement, not an FDA-label dispute, because UHC's covered indications (Pediatric GHD, Adult GHD, Transition Phase, PWS, SGA with no catch-up by 2–4, ISS with height SDS <-2.25) mirror the Norditropin label almost verbatim.

## The Step-Therapy Mechanic Is Where the Appeal Lives

This is not a medical-necessity fight — UHC has already conceded medical necessity by maintaining the indication on policy. The fight is procedural: did the plan honor the federal step-therapy override standard under 29 USC §1185d, and did it disclose the specific clinical criteria for an exception as required by 29 CFR §2560.503-1(g)? Most ERISA-governed UHC plans accept five override grounds: (1) the preferred drug is contraindicated or likely to cause adverse reaction; (2) the preferred drug is expected to be ineffective based on documented characteristics of the patient; (3) the patient has tried the preferred drug under any plan and it failed; (4) the patient is stable on Norditropin (continuity of care, relevant to mid-year plan switches and 45 CFR §156.122 ACA continuity); or (5) the preferred drug is not in the patient's best interest. Device-specific argument matters: NordiFlex's dose-dial granularity, pre-mixed liquid stability, and refrigeration profile differ materially from lyophilized pens — that is a 'documented characteristic of the drug' argument under ground (2).

## What Your Submission Must Contain

File through OptumRx's Prior Authorization line (not UHC medical), reference the HGH Medical Benefit Drug Policy version current to the date of service, and attach: (a) the GHD biochemical workup — ITT <5 ng/mL for Adult GHD, two provocative tests or IGF-1/IGFBP-3 plus auxologic data for pediatric; (b) endocrinologist attestation coordinating therapy (UHC requires this); (c) explicit override basis under §1185d with citation; (d) device-rationale paragraph distinguishing Norditropin from the preferred pen. UHC issues authorizations in 12-month blocks, so frame the request as a full year and pre-empt the renewal cycle.

## Tactical Tip

If UHC denies the override, demand the full administrative record under 29 CFR §2560.503-1(h)(2)(iii) — including the internal clinical reviewer's credentials, the rebate-tier rationale, and any non-public OptumRx criteria. Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) places the burden on the plan to substantiate clinical denials with record evidence; an opaque step-therapy denial that won't disclose the comparative-effectiveness basis collapses under that standard at external review.